Patents Issued in January 30, 2020
  • CRYSTALLINE SODIUM SALT OF 5-METHYL-(6S)-TETRAHYDROLIC ACID
    Publication number: 20200030333
    Abstract: The present invention is directed to a crystalline sodium salt of 5-methyl-(6S)-tetrahydrofolic acid wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to sodium is from 1:0.5 to 1:1.
    Type: Application
    Filed: March 28, 2018
    Publication date: January 30, 2020
    Applicant: Merck Patent GmbH
    Inventors: Rudolf MOSER, Viola GROEHN, Fritz BLATTER, Martin SZELAGIEWICZ, Ruth BOEHNI STAMM, Markus RUETTIMANN, Giuseppe LAPADULA
  • PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF DRY EYE AND METHODS FOR FABRICATING AND USING THEREOF
    Publication number: 20200030334
    Abstract: Methods and kits for improving tear production are described, along with topical pharmaceutical compositions. In certain instances the composition comprises pentoxifylline and a pharmaceutically acceptable carrier. The compositions also may further comprise another active agent, such as an anti-bacterial agent, antiviral agent, antifungal agent, or immunosuppressant agent, and combinations thereof.
    Type: Application
    Filed: July 26, 2019
    Publication date: January 30, 2020
    Inventors: John Scott Karolchyk, John P. Saharek
  • PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES
    Publication number: 20200030335
    Abstract: A compound of formula (I) wherein n is 0 to 4; m is 0 or 1 with the proviso that the sulphur atom and R3 are in vicinal position (if m=0 then R3 is in position 2?, and if m=1 then R3 is on position 1?); R is ethyl or vinyl; R1 is hydrogen or (C1-6)alkyl; R2 is hydrogen or —(C3-6)cycloalkyl, or —unsubstituted (C1-6)alkyl, or —(C1-6)alkyl substituted by one or more of —hydroxy; preferably one or two, —methoxy, —halogen, —(C3-6)cycloalkyl, or R1 and R2 together with the nitrogen atom to which they are attached form a 5 to 7 membered heterocyclic ring containing at least 1 nitrogen atom or 1 nitrogen and 1 additional heteroatome e.g. selected from N or O, or R1 is hydroxy and R2 is formyl; R3 is OH, OR4, a halogen atom, or —with the proviso that R3 is bound to 2? R3 represents —O—(CH2)P—O— with p is 2 or 3; R4 is unsubstituted (C1-6)alkyl or (C3-6)cycloalkyl.
    Type: Application
    Filed: October 4, 2019
    Publication date: January 30, 2020
    Inventors: Rosemarie Mang, Werner Heilmayer, Rudolf Badegruber, Dirk Strickmann, Rodger Novak, Mathias Ferencic, Atchyuta Rama Chandra Murty Bulusu
  • ANTIBIOTIC COMPOSITIONS FOR NASAL IRRIGATION AND METHODS
    Publication number: 20200030336
    Abstract: Provided herein are pharmaceutical formulations, nasal irrigation fluids, sachets, kits and the like comprising cephalosporin antibiotics, as well as methods of topical treatment of sinusitis and related conditions, methods of delivery of the formulations and fluids to the sinuses, methods of coating the sinuses, and methods of disruption and/or penetration of biofilms in the sinuses.
    Type: Application
    Filed: August 13, 2019
    Publication date: January 30, 2020
    Inventors: Kambiz Yadidi, Amanda Quiroga, Jagdeep Shur, Jeffrey B. Harris
  • DELIVERY OF ACTIVE AGENTS USING NANOFIBER WEBS
    Publication number: 20200030337
    Abstract: An active agent delivery system comprising a nanofiber web and an active agent carried by the nanofiber web.
    Type: Application
    Filed: June 13, 2019
    Publication date: January 30, 2020
    Inventors: Robert DiLuccio, Randy Milby
  • PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM
    Publication number: 20200030338
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
    Type: Application
    Filed: October 1, 2019
    Publication date: January 30, 2020
    Inventor: Herriot Tabuteau
  • TREATMENT CANCERS USING A COMBINATION COMPRISING PARP INHIBITORS
    Publication number: 20200030339
    Abstract: Disclosed herein is a method for the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject in need thereof a PARP inhibitor, particularly, (R)-2-fluoro-10a-methyl-7,8,9,10,10a,11-hexahydro-5,6,7a,11-tetraazacyclohepta[def]cyclopenta[a]fluoren-4(5H)-one, a sesqui-hydrate thereof, or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor or a chemotherapeutic agent. Also, disclosed a pharmaceutical combination comprising a PARP inhibitor, particularly, (R)-2-fluoro-10a-methyl-7,8,9,10,10a,11-hexahydro-5,6,7a,11-tetraazacyclohepta[def]cyclopenta[a]fluoren-4(5H)-one, a sesqui-hydrate thereof, or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor, or a chemotherapeutic agent and the use thereof.
    Type: Application
    Filed: September 27, 2017
    Publication date: January 30, 2020
    Inventors: Lai Wang, Zhiyu Tang, Lusong Luo, Min Wei, Kang Li, Jing Song, Tong Zhang, Hexiang Wang, Bo Ren, Changyou Zhou
  • DRUG THERAPY FOR PREVENTING OR TREATING GLAUCOMA
    Publication number: 20200030340
    Abstract: There is provided a drug therapy for prevention of glaucoma or prevention or treatment of ocular hypertension, with a potent ocular hypotensive effect and prolonged duration thereof. Disclosed is a combination of (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate thereof, and a prostaglandin for prevention or treatment of glaucoma.
    Type: Application
    Filed: September 4, 2019
    Publication date: January 30, 2020
    Applicant: KOWA CO., LTD.
    Inventor: Ken MIZUNO
  • METHOD FOR THE TREATMENT OF DRAVET SYNDROME
    Publication number: 20200030341
    Abstract: A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.
    Type: Application
    Filed: October 8, 2019
    Publication date: January 30, 2020
    Applicants: THE KATHOLIEKE UNIVERSITEIT LEUVEN, UNIVERSITY HOSPITAL ANTWERP
    Inventors: Berten CEULEMENS, Lieven LAGAE
  • DEHYDROEPIANDROSTERONE (DHEA) SUPPLEMENTATION ON FEMALE SEXUAL DESIRE AND FUNCTION IN PRE-MENOPAUSAL WOMEN
    Publication number: 20200030342
    Abstract: A method of improving sexual function in premenopausal women, who have low Female Sexual Function Index (FSFI) baseline of less than or equal to 25.7. The method includes providing information to premenopausal women to provide input for calculating the FSFI score and, if the score is low, providing dehydroepiandrosterone (DHEA) supplementation to be taken in 25 mg dosages daily once, twice, thrice or four times over a period of time of four to six weeks. By the end of the period of time, the FSFI baselines of the premenopausal women improves by at least seven percent, serum androgen levels of the premenopausal women increase and follicle-stimulating hormone (FSH) levels of the premenopausal women decrease.
    Type: Application
    Filed: July 27, 2018
    Publication date: January 30, 2020
    Applicants: American Infertility of New York, P.C.
    Inventors: Norbert Gleicher, Vitaly A. Kushnir, David H. Barad
  • ANTI-CANCER EFFECTS OF JAK2 INHIBITORS IN COMBINATION WITH THALIDOMIDE DERIVATIVES AND GLUCOCORTICOIDS
    Publication number: 20200030343
    Abstract: The present invention provides methods of treatment for hematological malignancies involving synergistic combination of a JAK2 inhibitor and a glucocorticoid or a JAK2 inhibitor, thalidomide or thalidomide derivative, and a glucocorticoid. The compositions and methods provide an unexpected efficacy in the treatment for hematological disorders. The hematological disorders treated by the current invention include multiple myeloma, and may also include hematological disorders that are refractory to prior cancer treatments, or a relapsed hematologic disorder.
    Type: Application
    Filed: May 7, 2019
    Publication date: January 30, 2020
    Applicant: OncoTracker, Inc.
    Inventor: James R. BERENSON
  • METHODS AND COMPOSITIONS RELATED TO GLUCOCORTICOID RECEPTOR ANTAGONISTS AND BREAST CANCER
    Publication number: 20200030344
    Abstract: Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound.
    Type: Application
    Filed: October 8, 2019
    Publication date: January 30, 2020
    Inventors: Deng PAN, Masha KOCHERGINSKY, Suzanne D. CONZEN
  • VIRAL PROPHYLAXIS TREATMENT METHODS AND PRE-EXPOSURE PROPHYLAXIS KITS
    Publication number: 20200030345
    Abstract: The present disclosure provides compositions and methods for the prevention of HSV infection in an HSV seronegative individual.
    Type: Application
    Filed: July 24, 2018
    Publication date: January 30, 2020
    Inventors: Emidio A. Checcone, Christina Ramirez
  • PHARMACEUTICAL COMPOSITION COMPRISING DAPAGLIFLOZIN
    Publication number: 20200030346
    Abstract: The present invention relates to solid oral pharmaceutical compositions comprising amorphous dapagliflozin. The invention further relates to a process for the preparation of the said pharmaceutical compositions. The said compositions are administered orally for the treatment of diabetes mellitus. The said compositions provide the desired immediate release of dapagliflozin and were found to be stable under accelerated conditions.
    Type: Application
    Filed: February 27, 2018
    Publication date: January 30, 2020
    Inventors: Vaibhavi Shah, Vijayendrakumar Redasani, Anant Ghongade
  • ANTIMICROBIAL COMPOSITIONS
    Publication number: 20200030347
    Abstract: Compositions for generating antimicrobial activity are described. The compositions comprise an enzyme that is able to convert a substrate to release hydrogen peroxide, a substrate for the enzyme, and a solute in the form of a sugar or sugar derivative having a solubility of at least 100 g/100 g water at 20° C. and 1 atm. The compositions may not comprise sufficient free water to allow the enzyme to convert the substrate.
    Type: Application
    Filed: October 6, 2017
    Publication date: January 30, 2020
    Inventors: David Kershaw, Matthew Dryden, Ian Staples, Sophie Constance Cox, Thomas Jon Hall, Liam Michael Grover, Rami Salib
  • INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING CORONARY DISORDERS
    Publication number: 20200030348
    Abstract: A method of treating preventing, minimizing, and/or reversing congestive heart failure, cardiomyopathy, and/or reduction of cardiac ejection fraction in a subject in need thereof includes administering to the subject a therapeutically effective amount of a 15-PGDH inhibitor.
    Type: Application
    Filed: April 9, 2018
    Publication date: January 30, 2020
    Inventors: Sanford Markowitz, Won Jin Ho, Yiyuan Yuan, Mukesh Jain, Mohamed Sabeh, Joseph Ready, Noelle Williams
  • PHYSIOLOGICALLY ACTIVE PREPARATION COMPRISING N-ACETYL-GLUCOSAMINE FOR THE TREATMENT OF BACK PAIN
    Publication number: 20200030349
    Abstract: A physiologically active composition for use in a method for the prophylaxis and/or treatment of back pain comprises N-acetyl-glucosamine or a suitable derivative of N-acetyl-glucosamine.
    Type: Application
    Filed: March 28, 2018
    Publication date: January 30, 2020
    Applicant: Natural Products & Drugs GmbH
    Inventor: Josef Schantl
  • Composition, For Remedying Female Climacteric Syndrome Symptoms, Comprising Tectorigenin 7-O-Xylosylglucoside
    Publication number: 20200030350
    Abstract: The present disclosure relates to a composition for preventing, treating or remedying female climacteric syndrome symptoms, which contains tectorigenin 7-O-xylosylglucoside. The composition according to the present disclosure shows quick effects for preventing, remedying and/or treating female climacteric syndrome symptoms, particularly facial flushing and/or osteoporosis, and thus can be utilized for the hormone replacement therapy (HRT) used for preventing or remedying climacteric syndrome symptoms.
    Type: Application
    Filed: July 18, 2017
    Publication date: January 30, 2020
    Applicant: LG Household & Health Care Ltd.
    Inventors: Bo-Young Lee, Ho-Song Cho, Soon-Ran Song, Won-Kyung Lee, Chang-Il Choi, Sang-Hwa Lee
  • USE OF CARRIMYCIN AND PHARMACEUTICALLY ACCEPTABLE SALTS OF CARRIMYCIN IN MANUFACTURING MEDICAMENT FOR TREATING AND/OR PREVENTING TUMOR
    Publication number: 20200030351
    Abstract: The present disclosure provides use of carrimycin and pharmaceutically acceptable salts thereof for the preparation of a medicament for the treatment of tumors. The carrimycin and the pharmaceutically acceptable salts thereof have good curative effects on breast cancer, liver cancer, lung cancer, renal cancer, brain tumor, cervical cancer, prostate cancer, pancreatic cancer, esophageal cancer, gastric adenocarcinoma, colon cancer, lymphoma or leukemia and other tumors, and especially have obvious inhibitory effects on the growth of human breast cancer cells MCF-7 and MDA-MB-231, human hepatoma cells HepG2, human non-small cell lung cancer cells A549, human large cell lung cancer cells H460 and H1299, human renal clear cell adenocarcinoma cell 786-O, human renal cell adenocarcinoma cell 769-P, and human glioma cell U251.
    Type: Application
    Filed: April 5, 2018
    Publication date: January 30, 2020
    Applicant: SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY CO., LTD.
    Inventors: Enhong JIANG, Mingyu XIA, Xunlei JIANG, Xundong JIANG
  • METHOD FOR TREATING CROHN'S DISEASE USING TRIPLE ANTIMICROBIAL ALL-IN-ONE FORMULATION
    Publication number: 20200030352
    Abstract: Oral administration of a solid dosage form of the present invention comprising an effective amount of rifabutin, an effective amount of clarithromycin, an effective amount of clofazimine, and an effective amount of an absorption enhancer, is used to treat a subject suffering from, or susceptible to, Mycobacterium avium subspecies paratuberculosis infection. In an embodiment, the solid dosage form is sufficiently designed to result in a reduction in the increased metabolism of clarithromycin caused by rifabutin. In an embodiment, the solid dosage form is sufficiently designed to result in a reduction in the metabolism of rifabutin caused by clarithromycin. In an embodiment, the solid dosage form is sufficiently designed to result in a reduction in risk of a subject developing leucopenia or uveitis as a result of rifabutin.
    Type: Application
    Filed: August 28, 2019
    Publication date: January 30, 2020
    Inventors: Thomas Julius Borody, Patrick Gosselin
  • STIMULATING PLATELET GENERATION BY ACTIVATING MITOCHONDRIAL BIOGENESIS
    Publication number: 20200030353
    Abstract: A method of stimulating platelet formation using a drug that stimulates mitochondrial biogenesis is described. The drug can be used to treat a subject that has been diagnosed with thrombocytopenia or a relatively low platelet count, or it can be used to stimulate platelet generation in vitro or ex vivo. Low-level light (LLL) therapy can be used together with the drug to stimulate mitochondrial biogenesis.
    Type: Application
    Filed: June 27, 2017
    Publication date: January 30, 2020
    Inventor: Meixiong WU
  • COMPOSITIONS AND METHODS FOR TREATING AN INFECTION
    Publication number: 20200030354
    Abstract: A dry formulation may include one or more active agents including one or more anti-infective agents such as an anti-bacterial agent, anti-fungal agent, or other anti-active agent. The dry formulation may be prepared for administration by mixing the dry formulation with a diluent. In one example, the diluent is a hydrocortisone and acetic acid solution or a sodium chloride solution. The combined preparation may be administered to the ear or skin to treat or prevent an infection.
    Type: Application
    Filed: October 7, 2019
    Publication date: January 30, 2020
    Applicant: CMPD LICENSING, LLC
    Inventor: Jay Richard Ray, II
  • COMBINATION THERAPY FOR TREATING CANCER
    Publication number: 20200030355
    Abstract: The disclosure relates to combinations comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Application
    Filed: January 16, 2019
    Publication date: January 30, 2020
    Inventors: Christine KLAUS, Maria Alejandra RAIMONDI, Scott Richard DAIGLE, Roy MacFarlane POLLOCK, Vivek CHOPRA
  • PANCREATIC CANCER THERAPY AND DIAGNOSIS
    Publication number: 20200030356
    Abstract: The present disclosure provides a novel method for treating pancreatic cancer and pancreatitis. The disclosure pertains to antagonists of dopamine receptors, that when combined with a glycolysis inhibitor, and a cholesterol lowering agent inhibit the growth of pancreatic cells.
    Type: Application
    Filed: August 12, 2019
    Publication date: January 30, 2020
    Inventors: Pouria JANDAGHI, Yasser RIAZ ALHOSSEINI, Daniel Scott AULD, Veena SANGWAN
  • Morpholino Oligonucleotides Useful In Cancer Treatment
    Publication number: 20200030357
    Abstract: Disclosed are morpholino oligonucleotides that can be used to silence expression of MGMT, pharmaceutical compositions that include said morpholino oligonucleotides, and methods of using said morpholino oligonucleotides in the treatment of cancer, particularly methods that involve the use of radiation to deliver said morpholino oligonucleotides.
    Type: Application
    Filed: July 25, 2019
    Publication date: January 30, 2020
    Inventors: Prakash Ambady, Jeffrey Wu, Edward Neuwelt
  • USE OF VITAMIN COMPOSITION IN PREPARING DRUG FOR PREVENTING, TREATING, OR DELAYING ALZHEIMER'S DISEASE
    Publication number: 20200030358
    Abstract: A use of a vitamin composition in preparing a drug for preventing, treating, or delaying Alzheimer's disease. The composition comprises a B vitamins composition or an analog or derivative thereof, vitamin C or an analog or derivative thereof, or a combination of a B vitamins composition or an analog or derivative thereof with vitamin C or an analog or derivative thereof.
    Type: Application
    Filed: February 24, 2017
    Publication date: January 30, 2020
    Inventor: Mingdong Zhou
  • INHIBITION OF STRESS GRANULE FORMATION THROUGH MANIPULATION OF UBAP2L
    Publication number: 20200030359
    Abstract: Disclosed herein are UBAP2L targeting agents and use of such agents for the treatment of a neurodegenerative disorder. Further disclosed herein are methods of monitoring the progression of a neurodegenerative disorder and methods of determining the efficacy of a neurodegenerative disorder therapy.
    Type: Application
    Filed: June 4, 2019
    Publication date: January 30, 2020
    Inventors: Eugene Yeo, Sebastian Markmiller, En-Ching Luo
  • ß-1,6-GLUCAN THERAPEUTIC ANTIBODY CONJUGATES
    Publication number: 20200030360
    Abstract: The present invention encompasses embodiments in which a therapeutic antibody is conjugated to ?-1,6-glucan oligomers. Thus, the present invention includes, among other things, compositions including a therapeutic antibody conjugated to one or more ?-1,6-glucan oligomers. The present invention further includes, among other things, methods of making and/or using such ?-1,6-glucan conjugates. In certain embodiments, a ?-1,6-glucan conjugate of the present invention is useful as a therapeutic or in a method of therapy.
    Type: Application
    Filed: December 5, 2017
    Publication date: January 30, 2020
    Inventors: Gabriel Oscar Reznik, John James Kane, James Michael Siedlecki, Zuzana Dostalova, Isabelle Sansal-Castellano, Ifat Rubin-Bejerano, Hua Miao, Eric Steven Furfine
  • OLIGONUCLEOTIDES CONTAINING 2'-DEOXY-2'FLUORO-BETA-D-ARABINOSE NUCLEIC ACID (2'-FANA) FOR TREATMENT AND DIAGNOSIS OF RETROVIRAL DISEASES
    Publication number: 20200030361
    Abstract: The disclosure relates to synthetic oligonucleotides that bind at least a portion of a dimerization initiation site (DIS) of a retrovirus genomic ribonucleic acid (RNA) molecule. In some aspects, the synthetic oligonucleotides include a 2-deoxy-2-fluoroarabinonucleotide (2-FANA)-modified nucleotide sequence. In some embodiments, the 2-FANA-modified nucleotide sequence inhibits dimerization of retroviral genomes (e.g., an HIV genome). Other embodiments include methods of inhibiting expression of a retrovirus using the synthetic oligonucleotide, and methods of treating or preventing a retroviral infection.
    Type: Application
    Filed: September 23, 2017
    Publication date: January 30, 2020
    Inventors: John J. Rossi, Masad J. Damha, Veenu Aishwarya, Mayumi Takahashi, Haitang Li
  • NITRIC OXIDE-RELEASING POLYAMINOGLYCOSIDES AS BIODEGRADABLE ANTIBACTERIAL SCAFFOLDS AND METHODS PERTAINING THERETO
    Publication number: 20200030362
    Abstract: Provided herein are hyperbranched polyaminoglycosides, where in some embodiments, the hyperbranched polyaminoglycosides are covalently modified to store and release nitric oxide. Some embodiments pertain to methods of making and use of hyperbranched polyaminoglycosides. In some embodiments, the covalently modified hyperbranched polyaminoglycosides may be tailored to release nitric oxide in a controlled manner and are useful for eradication of both gram positive and gram negative bacteria as well as other microbes.
    Type: Application
    Filed: March 28, 2018
    Publication date: January 30, 2020
    Inventors: MARK H. SCHOENFISCH, LEI YANG
  • COMPOSITIONS OF HYALURONAN WITH HIGH ELASTICITY AND USES THEREOF
    Publication number: 20200030363
    Abstract: The present invention provides compositions comprising hyaluronan with high elasticity, as well as methods for improving joint function, reducing pain associated with joint function and treating osteoarthritis by introducing into a joint a therapeutically effective amount of a composition comprising hyaluronan with high elasticity.
    Type: Application
    Filed: July 2, 2019
    Publication date: January 30, 2020
    Inventors: Endre A. Balazs, Carlos Belmonte
  • HIGH ELASTICITY HYALURONAN COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20200030364
    Abstract: The present invention provides methods for alleviating pain and discomfort associated with a dry eye condition; methods for alleviating pain and discomfort while minimizing at least one skin imperfection; and methods for alleviating pain and discomfort while facilitating wound healing. The methods involve administering to a subject in need thereof a composition comprising hyaluronan with high elasticity.
    Type: Application
    Filed: July 2, 2019
    Publication date: January 30, 2020
    Inventors: Carlos Belmonte, Janet L. Denlilnger
  • PHARMACEUTICAL COMPOSITIONS WITH HYDRATING AND LUBRICATING ACTIVITY
    Publication number: 20200030365
    Abstract: The present invention discloses pharmaceutical compositions comprising ester derivatives of hyaluronic acid for use as a topical treatment in disorders of the vaginal mucosa characterised by loss of elasticity and hydration, such as vaginal dryness and/or atrophic vaginitis; said compositions can also be used successfully to lubricate the genital mucosa.
    Type: Application
    Filed: October 4, 2019
    Publication date: January 30, 2020
    Applicant: FIDIA FARMACEUTICI S.P.A.
    Inventors: Laura PILOTTO, Giovanni GENNARI, Anna Maria ZANELLATO
  • INULIN FOR PREVENTING ANTIBIOTIC RESISTANT INFECTION AND PATHOGEN COLONIZATION
    Publication number: 20200030366
    Abstract: The present disclosure provides for methods and compositions for the treatment and prevention of antibiotic-resistant infections or pathogen colonization in critically ill patients in the intensive care unit (ICU) or in other populations at high risk for such infections.
    Type: Application
    Filed: February 27, 2019
    Publication date: January 30, 2020
    Inventors: Julian Abrams, Daniel Freedberg
  • COMPOSITION FOR TREATING FIBROCARTILAGE TISSUE DAMAGE
    Publication number: 20200030367
    Abstract: The present invention has an objective of providing a novel composition for treating a fibrocartilaginous tissue injury. The present invention provides a composition for treating a fibrocartilaginous tissue injury, which is to be applied to an injured fibrocartilaginous tissue part of a target and which comprises a monovalent metal salt of alginic acid, more preferably a low endotoxin monovalent metal salt of alginic acid.
    Type: Application
    Filed: March 1, 2018
    Publication date: January 30, 2020
    Applicants: Mochida Pharmaceutical Co., Ltd, National University Corporation Hokkaido University
    Inventors: Eiji KONDO, Norimasa IWASAKI, Tomohiro ONODERA, Wooyoung KIM, Yasuyuki KAWAGUCHI
  • A POLYMER NETWORK, METHOD FOR PRODUCTION, AND USES THEREOF
    Publication number: 20200030368
    Abstract: The present disclosure relates to a polymer network comprising a compound of Formula I cross-linked to a compound selected from the group consisting of a compound of Formula II; hyaluronate aldehyde, alginate aldehyde, dextran aldehyde, starch aldehyde, and chitosan aldehyde. It also relates to a process of preparing the polymer network. The present disclosure further relates to compositions comprising the polymer network and methods of preventing conditions and diseases that are caused by micro-organism. The present disclosure still further relates to a biocompatible antimicrobial hydrogel, a process for preparing the hydrogel, and methods of using the same, including a variety of tissue-related applications in which rapid adhesion to the tissue and gel formation is desired, as well as local delivery of pharmaceutical drugs to a site of application.
    Type: Application
    Filed: July 28, 2017
    Publication date: January 30, 2020
    Inventors: Jayanta HALDAR, Jiaul HOQUE
  • Modified Immune-Modulating Particles
    Publication number: 20200030369
    Abstract: The current invention involves the surprising finding that when carboxylated particles, such as carboxylated poly-styrene, PLGA, or diamond particles are administered to subjects, inflammatory immune responses are ameliorated. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same carboxylated particles.
    Type: Application
    Filed: October 16, 2019
    Publication date: January 30, 2020
    Inventors: Daniel R. Getts, Rachael Terry, Nicholas King
  • METHOD FOR TREATING SCHIZOPHRENIA
    Publication number: 20200030370
    Abstract: A method for treating schizophrenia, comprising administering a composition containing a therapeutically effective amount of hydrogen gas to a subject in need of the treatment, by inhalation, is provided by the present invention.
    Type: Application
    Filed: July 24, 2019
    Publication date: January 30, 2020
    Inventors: Fumitake SATO, Masatsugu SAITO, Ryosuke KUROKAWA
  • METHOD OF ADMINISTRATION AND TREATMENT
    Publication number: 20200030371
    Abstract: Provided herein are formulations for topical and/or transdermal administration, and methods of using these formulations for the treatment of proliferative diseases related to cancer such as cancers and related conditions, and solid tumors. Also provided are formulations for topical and/or transdermal administration, and methods of using these formulations for melasma, gout, skin disorders, and other diseases and disorders described herein as well as methods for modulating the pH (e.g. raising) of a tissue or microenvironment proximal to a tumor, modulating pH, or improving the effectiveness of know chemotherapeutic agents, immunotherapy and the like for the prevention, treatment of cancers and related conditions described herein.
    Type: Application
    Filed: August 20, 2019
    Publication date: January 30, 2020
    Applicant: AMPERSAND BIOPHARMACEUTICALS, INC.
    Inventor: Ryan Beal
  • ALLEVIATING COMMON COLD AND INFLUENZA SYMPTOMS WITH MOLECULAR HYDROGEN
    Publication number: 20200030372
    Abstract: A method for alleviating, preventing or treating symptoms of a viral infection such as common cold and flu, comprising administering to a subject in need thereof at least one solid form that releases molecular hydrogen upon exposure to the subject's gastric juice.
    Type: Application
    Filed: July 30, 2019
    Publication date: January 30, 2020
    Inventors: Vladimir L. SAFONOV, Marina Yu SAFONOV
  • COMPOSITIONS AND METHODS FOR INTRACELLULAR IRON DISPLACEMENT PROTEINS
    Publication number: 20200030373
    Abstract: Methods and pharmaceutical compositions for optimizing intracellular iron by displacing iron bound transferrin (Tf) protein on a mammalian cell surface prior to its binding to a transferrin receptor (TfR), in the delivery of chromium chloride as being a Tf-binding agent to displace iron bound, and in the treatment of conditions involving disturbances in iron metabolism.
    Type: Application
    Filed: June 16, 2019
    Publication date: January 30, 2020
    Inventor: KENNETH O. RUSSELL
  • CELLULAR TARGETED ACTIVE INGREDIENT DELIVERY SYSTEM
    Publication number: 20200030374
    Abstract: The present invention relates to an isolated cellular targeted delivery system comprising a CD45+ leukocyte cell comprising within said cell a complex of one or more iron binding proteins and an active ingredient as well as methods for producing such isolated cellular targeted delivery system and uses of such system for therapy, in particular for therapy of cancer.
    Type: Application
    Filed: June 22, 2016
    Publication date: January 30, 2020
    Inventors: Magdalena KROL, Irene BENNI, Paola BAIOCCO, Tomasz RYGIEL, Alberto BOFFI
  • THERAPY AND METHODS OF INTRODUCING IMMATURE DENDRITIC CELLS AND/OR CYTOXIC T LYMPHOCYTE AND ANTI PD-1 / PD-L1 ANTIBODY FOR TREATMENT OF TUMORS
    Publication number: 20200030375
    Abstract: The invention relates to therapy and methods of applying the therapy to a patient. The invention includes the introduction of immature dendritic cells into the patient and the introduction of PD-1 and/or PD-L1 inhibitor into the patient. The immature dendritic cells are introduced intratumorally and/or through vessel and the PD-1 and/or PD-L1 inhibitor is introduced intratumorally and/or through vessel and/or subcutaneously. The immature dendritic cells can be formed by collecting monocyte cells from the patient and culturing the cells in a culture medium. The invention can be effective to regress, reduce or eliminate tumor cells in tumor tissue of the patients, including metastasized tumors. Further, the treatment of the invention is effective in the absence of conventional therapy, such as radiotherapy and chemotherapy.
    Type: Application
    Filed: May 6, 2019
    Publication date: January 30, 2020
    Inventor: KENICHIRO HASUMI
  • CELL THERAPY COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASE COMPRISING REGULATORY T CELLS AS ACTIVE INGREDIENT
    Publication number: 20200030376
    Abstract: The present invention relates to a cell therapy method for treating neurodegenerative diseases, which includes administering a therapeutically effective amount of a regulatory T cell to an individual in need thereof. The regulatory T cell may be an amyloid-beta specific regulatory T cell induced by administering amyloid-beta peptide and bee venom phospholipase A2 (bvPLA2).
    Type: Application
    Filed: July 27, 2018
    Publication date: January 30, 2020
    Applicant: GMP CO., LTD.
    Inventors: Hyun-Su Bae, Hyun-Jung Baek, Min-Sook Ye, Chan-Ju Lee
  • ANTIGEN-SPECIFIC IMMUNE MODULATION
    Publication number: 20200030377
    Abstract: The disclosure relates generally to methods of treating or preventing an autoimmune disease, for example diabetes, by activating PD-L1 in an antigen presenting cell.
    Type: Application
    Filed: September 22, 2017
    Publication date: January 30, 2020
    Inventor: Habib Zaghouani
  • HIGH AFFINITY MERKEL CELL POLYOMAVIRUS T ANTIGEN-SPECIFIC TCRS AND USES THEREOF
    Publication number: 20200030378
    Abstract: The present disclosure provides binding proteins and TCRs with high affinity and specificity against Merkel cell Poly-omavirus T antigen epitopes or peptides, T cells expressing such high affinity Merkel cell polyomavirus T antigen specific TCRs, nucleic acids encoding the same, and compositions for use in treating Merkel cell carcinoma.
    Type: Application
    Filed: November 14, 2017
    Publication date: January 30, 2020
    Inventors: Aude G. Chapuis, Paul T. Nghiem, Megan S. McAfee, Natalie J. Miller, Kelly Garneski Paulson, David Martin Koelle, Thomas M. Schmitt, Candice Church
  • CELL EXPRESSING A CAR AND A TRANSCRIPTION FACTOR AND ITS USE
    Publication number: 20200030379
    Abstract: The present invention provides a cell which comprises a first exogenous nucleic acid molecule encoding a Chimeric Antigen Receptor (CAR) and a second exogenous nucleic acid molecule encoding a transcription factor.
    Type: Application
    Filed: December 20, 2017
    Publication date: January 30, 2020
    Inventors: Martin Pulé, Simon Thomas, Shaun Cordoba, Wen Chean Lim
  • STIMULATION OF THERAPEUTIC ANGIOGENESIS BY T REGULATORY CELLS
    Publication number: 20200030380
    Abstract: Disclosed herein are new, useful, and non-obvious means of stimulating therapeutic angiogenesis, or conditions favorable for stimulation of therapeutic angiogenesis utilizing T regulatory cells. One disclosed method includes administering a population of T regulatory cells into an area of hypoxia to stimulate angiogenesis. T regulatory cells are generated and expanded by culture with mesenchymal stem cells, with either population or both populations together administered into the hypoxic area.
    Type: Application
    Filed: July 3, 2019
    Publication date: January 30, 2020
    Inventor: Thomas Ichim
  • COMPOSITIONS AND METHODS FOR INHIBITION OF LINEAGE SPECIFIC PROTEINS
    Publication number: 20200030381
    Abstract: Disclosed herein are compositions, methods, and kits for use in treating hematopoietic malignancies, the compositions, methods, and kits comprise a cytotoxic agent targeting cells expressing a lineage-specific cell-surface protein and a population of hematopoietic cells that express the lineage-specific cell-surface protein, the hematopoietic cells being manipulated such that they do not bind the cytotoxic agent.
    Type: Application
    Filed: February 28, 2018
    Publication date: January 30, 2020
    Applicant: VOR BIOPHARMA, INC
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • METHODS FOR LOWERING BLOOD GLUCOSE
    Publication number: 20200030382
    Abstract: The present invention provides a method for lowering blood glucose levels in an animal by transplanting a population of pancreatic endocrine precursor cells into an animal.
    Type: Application
    Filed: August 13, 2019
    Publication date: January 30, 2020
    Applicant: Janssen Biotech, Inc.
    Inventor: Jean Xu